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Background: Depression and cognitive impairment (CI) are important non-motor symptoms in Parkinson’s Disease
(PD) and related syndromes, but it is not clear how well they are recognised in daily practice. We have studied the
diagnostic performance of experienced neurologists on the topics depression and cognitive impairment during a
routine encounter with a patient with recent-onset parkinsonian symptoms.
Methods: Two experienced neurologists took the history and examined 104 patients with a recent-onset
parkinsonian disorder, and assessed the presence of depression and cognitive impairment. On the same day, all
patients underwent a Hamilton Depression Rating Scale test, and a Scales for Outcomes in Parkinson’s Disease-
Cognition-test (SCOPA-COG).
Results: The sensitivity of the neurologists for the topic depression was poor: 33.3%. However, the specificity varied
from 90.8 to 94.7%. The patients’ sensitivity was higher, although the specificity was lower. On the topic CI, the
sensitivity of the neurologists was again low, in a range from 30.4 up to 34.8%: however the specificity was high,
with 92.9%. The patients’ sensitivity and specificity were both lower, compared to the number of the neurologists.
Conclusions: Neurologists’ intuition and clinical judgment alone are not accurate for detection of depression or
cognitive impairment in patients with recent-onset parkinsonian symptoms because of low sensitivity despite of
high specificity.
Trial registration: (ITRSCC)NCT0036819.
Keywords: Mood disorder, Dementia, Non-motor, Parkinson’s diseaseBackground
Depression and cognitive impairment (CI) are increas-
ingly appreciated as important non-motor symptoms in
patients with Parkinson’s disease (PD) and related syn-
dromes [1-11]. Early recognition and diagnosis of both is
important as treatment may increase quality of life of
patients [12-22], but this is reported to be hampered at
different levels. Many depressed patients are not aware of
their problems [23] and, although caregivers sometimes
have better judgment [24], they can also be misled by
personality issues [25]. Non-psychiatrist physicians* Correspondence: A.Bouwmans@mumc.nl
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distribution, and reproduction in any mediumappear not to do much better, as numerous studies
have shown that they perform significantly worse than
validated questionnaires [26-39]. The presence of CI
also leads physicians to overestimate the presence of
depression [40].
Non-motor symptoms in PD tend to be under-
diagnosed compared to motor problems, which seems
logical as the latter are the primary expertise of neurolo-
gists. Some studies have compared different instruments
to diagnose CI and depression in PD [41-43], but few
have studied how accurate the diagnostic process is in
normal daily practice [44,45]. Most often, neurologists
focus on motor symptoms and evaluate possible CI and
depression implicitly during their consultation [46].
These consultations are often too short to conduct a for-
mal validated test for depression and/or CI. We studieded Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Flowchart of our study.
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consecutive series of patients referred for analysis of a
parkinsonian disorder of very recent onset. We focused
on this patient group as research on this question has
hitherto been done only in patients with a well-
established diagnosis of PD.
Methods
The present study was nested in a larger, prospective
study testing the diagnostic accuracy of transcranial du-
plex scanning (TCD) of the substantia nigra (SN) in the
brainstem as an instrument to diagnose PD in patients
with a parkinsonism of unclear origin [47].
We invited 283 consecutive patients, who were re-
ferred to two neurology outpatient clinics, for analysis of
clinically unclear parkinsonian disorder (Neurology Out-
patient Clinics of the Maastricht University Medical
Centre in Maastricht and of the Maasland Hospital in
Sittard, both in The Netherlands). Patients, whose par-
kinsonism was clearly diagnosable at the first visit, were
excluded from the study. For further details see our
protocol described elsewhere [47]. Finally, we enrolled
242 patients in our study (see Figure 1) after written
informed consent for participation by each patient.
After two years, all patients were re-examined by a
pair of neurologists for a final clinical diagnosis. The
neurologists were specialists in movement disorders,
with more than ten years’ experience in this field. These
investigators were blinded for all prior test results from
these patients. In planning these visits, we made sure
that neither of the two neurologists had ever seen the
patient. They were asked to interview and examine the
patient, guided by a standard form (see Additional file
1). Family or spouse were allowed to be present at this
consultation, but were asked to refrain from answering
any questions. Neurologists were not given any objective
scales for depression or cognitive impairment. After this
consultation, the patient left the room.
The specialists were then asked to indicate on a form
if they thought the patient was depressed and if CI was
present. There was no communication between the
raters on this decision. They were also asked to reach an
independent clinical diagnosis, and record it. After this,
they were asked to discuss the patient, and reach a final,
consensus diagnosis, which served as the “gold standard”
in the TCD study [47]. On the day of this evaluation, all
patients were asked to complete the Hamilton Depres-
sing Rating Scale (in the text further shortened to ‘Ham-
ilton’) and the Scales for Outcomes in Parkinson’s
Disease-Cognition (SCOPA-COG). Both tests have
shown their reliability and validity as instruments to as-
sess either depression or CI, both with and without PD
[48-53]. The maximum possible score on the SCOPA-
COG is 43. A score of 20 or lower is defined as CI[52,53]. The maximum possible score on the 17 item
Hamilton is 52. A score 0 to 7 on the Hamilton implies
normal/-borderline mood, score between 8 and 15 indi-
cates a mild depression; a score in the range of 16 to 26
indicates a moderate depression; and a score of 27 or
higher implies severe depression [50,51]. The results of
these tests were not provided to the patients. We also
asked the patients the following questions: ‘Do you think
you have more difficulties with your memory than
people of the same age as you?’ and ‘Did you experience
feelings of depression, most of the time during the last
month?’ to evaluate their insight about the presence of
CI and depression.
The primary objective of this study was to define the
accuracy, namely, the sensitivity and specificity of the
neurologists’ clinical judgement regarding the presence
of CI and depression. The secondary objective was to
evaluate the degree of agreement on the diagnosis of CI
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two neurologists. SPSS 16.0 for windows (SPSS, Chi-
cago, IL, USA) was used for statistical analysis. The ac-
curacy of the clinical judgement of the neurologists
was evaluated by the means of specificity and sensitiv-
ity. The inter-rater agreement was evaluated by the
Kappa statistics.
Results
We had originally enrolled 242 patients into the TCD
study (see Figure 1). Follow-up after two years took
place between September 2008 and September 2010.
Thirty patients (12,4%) had died and 108 patients
(44,2%) were unable or unwilling to undergo a second
evaluation. The group lost to follow up were signifi-
cantly older (p = 0,034) and had a higher mean Unified
Parkinson’s Disease Rating Scale (UPDRS) at enroll-
ment (p = 0,031). However there were no significant
differences in the distribution of the final diagnoses
compared to the patients included in the present
study. No correlation was found between either the
UPDRS scores or results on the Hamilton and
SCOPA-COG and the final diagnoses after two years
follow-up.
For the present study, 104 patients (65 male, 39 fe-
male) were evaluated. The mean age was 70,3 (range
44–90) years. After two years follow-up, 62,5% of the
patients used antiparkinson medication,13,5% antide-
pressants, and 3,8% neuroleptics. No one used cognitive
enhancers. The final clinical diagnosis was PD in 53
(51%) patients. For further patient characteristics, see
Table 1. The diagnostic groups were demographically
similar. The remaining 15 (14%) patients without parkin-
sonism had alternative diagnoses, such as, isolated
tremor, orthostatic tremor, tardive dyskinesia, multi-
infarct dementia, Alzheimer disease, stroke, hypoxic en-
cephalopathy, and psychogenic disorder.Table 1 Patient characteristics (data as mean and SD) or coun
All patients
(n = 104)
PD (n= 53) APS
Mean age in years (SD) 70,3 (9,46) 69,81 (9,74) 70,29
Men 64% 63% 75%
Mean score UPDRS-III (SD) 15,03 (8,08) 16,88 (6,06) 19,57
SCOPA-COG >20 (no CI) 55% 58% 67%
SCOPA-COG<=20 (yes CI) 45% 42% 33%
Hamilton< 8 (no depression) 74% 81% 54%
Hamilton>=8 (yes depression) 26% 19% 46%
‘Self-diagnosed’ presence of CI 38% 34% 69%
‘Self-diagnosed’ presence of depression 18% 13% 23%
PD=Parkinson’s disease, APS=atypical parkinsonian syndromes, VP=vascular parkinso
Parkinson’s Disease Rating Scale part III, SCOPA-COG=Scales for Outcomes in Parkinso
impairment.Cognitive impairment
In total 102 patients were able to complete the SCOPA-
COG, two patients were too tired after the consultation
with the neurologists, and therefore, were not able to
complete this test. The mean SCOPA-COG score was
21,1 with a range of 4 to 36. See Table 2 for the results
on CI ‘diagnoses’ by the neurologist compared with the
SCOPA-COG scores.
The sensitivity of neurologist 1 for ‘diagnosing’ CI was
34,8% and of neurologist 2 30,4% (see Table 3). Specifi-
city of both neurologists was 92,9%.
In answer to the question ‘Do you think you have
more difficulties with your memory than people of the
same age as you?’, 19 (18,6%) said ‘yes’, 77 (75,5%) said
‘no’, and 6 (5,9%) ‘I do not know’. See Table 2 for the
results on this ‘self-diagnosis’ of the patients on CI com-
bined with their SCOPA-COG scores. Because six
patients could not answer the question with ‘yes’ or ‘no’,
we excluded them from this analysis. Therefore the sen-
sitivity of self-diagnosis of CI by the patient was 27,3%.
Its specificity was 86,5%.
The agreement between neurologist 1 and neurologist
2 was good with a kappa value of 0,74 (95% confidence
interval 0,57–0,91) (see Table 3). However, the agree-
ment between the neurologists and the patient was
much lower with a kappa value varying between 0,34
(95% confidence interval 0,12–0,56) and 0,44 (95% confi-
dence interval 0,23–0,66).
Depression
In total, 103 patients were able to complete the Hamil-
ton (one patient was too tired after the consultation and
was not able to complete this test). The mean Hamilton
score was 5,5 with a range of 0 to 26. In this study, none
of the patients had a score of 27 or higher. We defined
depression at the total score of 8 or higher on the
Hamilton.t (%)
(n = 13) VP (n = 8) ET (n= 11) DIP (n = 4) No parkinsonism
(n= 15)
(7,42) 73,71 (1,60) 67,91 (10,38) 67,50 (12,61) 72,44 (11,06)
56% 91% 50% 47%
(9,94) 18,29 (9,55) 6,82 (3,95) 17,00 (10,86) 8,75 (6,18)
38% 82% 25% 60%
62% 18% 75% 40%
71% 73% 100% 60%
29% 27% 0% 40%
25% 18% 50% 47%
13% 36% 25% 20%
nism, ET=essential tremor, DIP=drug induced parkinsonism, UPDRS-III = Unified
n’s Disease-Cognition, Hamilton=Hamilton Depressing Rating Scale CI= cognitive
Table 2 Results of neurologists’clinical assessment and patients’ insight versus SCOPA-COG and Hamilton scores (data
in numbers)
Rater 1 Rater 1 Rater 2 Rater 2 Patient Patient Patient
yes no yes no yes no do not know
SCOPA-COG> 20 (no CI) 4 52 4 52 7 45 4
SCOPA-COG<=20 (yes CI) 16 30 14 32 12 32 2
Hamilton< 8 (no depression) 7 69 4 72 21 49 6
Hamilton>=8 (yes depression) 9 18 9 18 19 7 1
SCOPA-COG = Scales for Outcomes in Parkinson’s Disease-Cognition, Hamilton =Hamilton Depressing Rating Scale, CI = cognitive impairment.
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by the neurologists compared to the patients’ Hamilton
score. The sensitivity of depression diagnosis by both
neurologists was 33,3%, specificity of neurologist 1 was
90,8% and of neurologist 2 was 94,7% (see Table 3).
In answer to the question ‘Did you experience feel-
ings of depression, most of the time this last month?’,
40 (38,8%) said ‘yes’, 56 (54,4%) said ‘no’, and 7 (6,8%)
‘I do not know’. See Table 2 for the results on ‘self-
diagnosis’ by the patients compared with their Hamil-
ton score. Because 7 patients could not answer the
question with ‘yes’ or ‘no’, we excluded them from this
analysis. Therefore, the sensitivity of the patients’ self-
diagnosis of depression was 73,1%. Its specificity was
70,0%.
The agreement between neurologist 1 and neurolo-
gist 2 was good with a kappa value of 0,62 (95% confi-
dence interval 0,39–0,85) (see Table 3). Agreement
between neurologists and patients was lower, with a
kappa value varying between 0,28 (95% confidence
interval 0,12–0,43) and 0,43 (95% confidence interval
0,27–0,60).Table 3 Summary of the neurologists’ and patients’
diagnostic performance
CI Depression
Rater 1 specificity 92.9% 90.8%
Rater 1 sensitivity 34.8% 33.3%
Rater 2 specificity 92.9% 94.7%




0.74 (0.57–0.91) 0.62 (0.39–0.85)
Patient specificity 86.5% 70.0%








0.44 (0.23–0.66) 0.28 (0.12–0.43)Discussion
We studied the accuracy of neurologists’ ability to diag-
nose depression and CI in patients with parkinsonian
symptoms, in a way that most closely resembles normal
daily clinical neurology practice, as a definite diagnosis
of a parkinsonian syndrome is often not possible in the
first few years. And, while the neurologists in our study
were very experienced in PD and spent on average more
time per patient than normal, we speculate that their
results might even be somewhat inflated.
A limitation of the study is the use of psychometric
scales as a proxy for the diagnoses of CI and depression.
While these can not, of course, replace a complete diag-
nostic work-up by a specialised psychiatrist with a psy-
chometric battery, we do feel that the results show that
there is probably a considerable underestimation of the
presence of these clinical problems also in patients with
a very recent-onset of a parkinsonian disorder. Another
limitation of our study is the large number of patients
lost to follow-up. This could have biased our population
towards one with less morbidity, thus increasing diag-
nostic difficulty. From the age and UPDRS-scores one
can infer that PD patients with more severe disease and
thus with possibly more severe depression and CI were
underrepresented in this study.
We found that this implicit diagnostic process by neu-
rologists is far less accurate than validated tests. The
prevalences of both depression and CI found in our
study, are representative for the general population of
PD patients [54,55].
We found that neurologists underestimated the num-
ber of patients with CI, by up to 70%. They did some-
what better than the patients themselves. Compared to
other studies, our neurologists’ diagnostic sensitivity for
CI was lower than those of general practitioners (GP’s),
although both had a high specificity [34-40]. Our data
on the recognition of CI are in line with two earlier
studies on PD patients, which both found the majority
of symptoms going unrecognised and untreated. How-
ever, one of those was a retrospective chart review and
the other, prospective, study involved older, well-
established PD patients. We did not confirm earlier
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of depression by doctors [40].
In ‘diagnosing’ depression, our neurologists showed low
sensitivity and high specificity. ‘Self-diagnosis’ of depression
by the patient had a higher sensitivity compared to the neu-
rologists, although the specificity was lower. The neurolo-
gists missed up to 67% of the patients with depression. The
patients in our study overestimated the presence of depres-
sion. Presence of CI had no influence on the insight of the
patients on depression. ‘Diagnostic accuracy’ of depression
by our neurologists was comparable to GP’s [26], but self-
diagnosis of depression in our patient population had a re-
markably higher sensitivity than in an earlier study done by
Watson [24]. However, that study only included patients
with dementia, and this may explain this difference.
Conclusions
Intuition and clinical judgment are not enough for a neur-
ologist to recognize depression and/or cognitive problems
in patients with recent-onset parkinsonian syndromes,
such as, PD and atypical parkinsonian syndromes (APS).
It is important to realize this, considering the conse-
quences of untreated depression and CI. Our neurologists
had a high specificity diagnosing CI and depression, but at
the same time missed more than half of the patients with
these problems. Patients themselves are not better at self-
diagnosing these non-motor symptoms.
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